OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the successfully completion of cGMP manufacturing of 9,042 clinical...
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that it has taken an essential step forward in testing the...
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), today announced the next CEO Corner segment has been published on the Company's...
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), today announced the next CEO Corner segment has been published on the Company's...
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop...
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), today announced the next CEO Corner segment has been published on the Company's...
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (€œAIM€) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda...
Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indications Company to host conference call and webcast today, April 2nd at 8:30 AM...
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results